Aradigm Announces Sale of Assets to Grifols, S.A.
Aradigm Announces Sale of Assets to Grifols, S.A.
Aradigm Corporation (OTC PINK: ARDM) (“Aradigm” or the “Company”) announced on March 30, 2020, the Bankruptcy Court entered an order approving the sale by Aradigm Corporation (the “Company”) to Grifols, S.A. (the “Buyer”) of the Company's assets and intellectual property that pertain to Lipoquin, Free Ciprofloxacin, Apulmiq and any derivatives thereof. The Buyer has advised the Company that the Buyer has entered into an agreement with a third party to license to the third party the intellectual property and other rights the Buyer acquired from the Company and that the third party has agreed to pursue the development and commercialization of the Aradigm products.
阿瑞迪格姆股份有限公司 （場外粉紅色：ARDM）（「阿拉迪格姆」或「公司」）於 2020 年 3 月 30 日宣布，破產法院簽署了由阿拉迪格姆公司（「該」公司」) 到格里弗爾, S.A. (該」買家」) 本公司的資產及知識產權屬於 Lipoquin、自由環丙沙星、阿普爾米克及其任何衍生物。買方已通知本公司，買方已與第三方達成協議，向第三方授權買方從本公司獲得的知識產權和其他權利，並且第三方已同意進行 Aradigm 產品的開發和商業化。
The purchased assets include all Intellectual Property Assets and Patents that pertain to Lipoquin, Free Ciprofloxacin, Apulmiq and any derivatives thereof, the information and know-how that Aradigm controls that is related to or useful for the development of an Aradigm Product, including protocols, manufacturing processes, and technical and sourcing information, all filings, submissions, applications, reports or correspondence between Aradigm and any Regulatory Agency related to the purchased assets, and records and reports including all pharmacological, pre-clinical, clinical, analytical and quality control data, results and material correspondence related to the purchased assets.
購買的資產包括與 Lipoquin，Free Ciprofloxacin，Aulmiq 及其任何衍生物有關的所有知識產權和專利，Aradigm 控制的信息和專業知識與開發 Aradigm 產品有關或有用的信息，包括協議，製造工藝以及技術和採購信息，所有文件，提交，申請和監管機構之間的所有文件，報告或信函，Aradigm 與購買的資產有關，以及記錄和報告，包括所有藥理學，預與購買資產有關的臨床、臨床、分析和質量控制數據、結果和材料對應。
Excluded from the sale are all of the Company's cash and cash equivalents, accounts or notes receivable, certain contracts, tangible personal property, the name Aradigm Corporation, accounts and records of Aradigm Corporation, all benefit plans and the shares of Aradigm.
從銷售中排除所有公司的現金和現金等價物，賬戶或應收票據，某些合同，有形的個人財產，名稱 Aradigm 公司，賬戶和 Aradigm 公司的記錄，所有福利計劃和 Aradigm 的股份。
The purchase price is cash of $3,247,000 payable at Closing, waiver of Proof of Claim No. 4 in the amount of $19,950,000 filed by the Buyer in the Company's bankruptcy case, waiver of Proof of Claim No. 5 in the amount of $11,785,898.96 filed by the Buyer's affiliate in the bankruptcy case, a milestone payment of $2 million payable upon approval of any Aradigm product by the FDA, a milestone payment of $1 million payable upon approval of any Aradigm product by the EMA, and during the Royalty Term, the Company will receive twenty-five percent of any royalties received by the Buyer.
購買價格為買方在公司破產案件中提交的 19,950,000 美元金額豁免索賠證明第 4 號，豁免申索證明第 5 號的現金，購買者關聯公司在破產案件中提交的 11,785,898.96 美元的索賠證明第 5 號豁免，在任何 FDA 支付里程碑時，Ardigam 產品批准後的里程碑付款為 200 萬美元在 EMA 批准任何 Aradigm 產品後支付 100 萬美元，在版稅期間，公司將獲得任何特許權使用費的百分之二十五由買方收到。
The Sale closed on March 31, 2020.
此次促銷活動已於 2020 年 3 月 31 日結束。
About Aradigm
關於阿拉迪格姆
Aradigm is an emerging specialty pharmaceutical company focused on the development and commercialization of drugs for the prevention and treatment of severe respiratory diseases. Inhaled ciprofloxacin formulations are also product candidates for treatment of patients with cystic fibrosis and non-tuberculous mycobacteria, and for the prevention and treatment of high threat and bioterrorism infections, such as inhaled tularemia, pneumonic plague, melioidosis, Q fever and inhaled anthrax.
Aradigm 是一家新興的專業製藥公司，專注於開發和商業化用於預防和治療嚴重呼吸系統疾病的藥物。吸入環丙沙星配方也是用於治療囊性纖維化和非結核分枝桿菌患者的候選產品，以及用於預防和治療高威脅和生物恐怖主義感染，例如吸入土拉血症、肺炎鼠疫、類鼻疽、Q 熱和吸入性炭疽。
Forward-Looking Statements
前瞻性陳述
Except for the historical information contained herein, this news release contains forward-looking statements that involve risk and uncertainties, including the risk that Apulmiq may not receive regulatory approval or be successfully commercialized, as well as the other risks detailed from time to time in the Company’s filings with the Securities Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K for the year ended December 31, 2017 filed with the SEC on March 23, 2018, and the Company’s Quarterly Reports on Form 10-Q.
除本文所載的歷史資料外，本新聞稿載有涉及風險和不明朗因素的前瞻性陳述，包括 Aulmiq 可能無法獲得監管批准或成功商業化的風險，以及公司於 2017 年 12 月 31 日向證券交易委員會（SEC）提交的 10-K 表中不時詳述的其他風險，包括公司截至 2017 年 3 月 31 日止年度的 10-K 表格的年報 2018 年，以及本公司第 10-Q 表季度業績報告。
More information about Aradigm can be found at www.aradigm.com.
有關阿拉迪格姆的更多信息可以在以下位置找到。
譯文內容由第三人軟體翻譯。